Royalty Pharma has entered a $500 million co-funding agreement with Johnson & Johnson for 2026-2027 to advance JNJ-4804, a novel co-antibody therapy targeting chronic immune-mediated diseases. This drug blocks IL-23 and TNF pathways, offering synergistic effects for autoimmune conditions. The collaboration highlights Royalty Pharma's ongoing commitment to immunology innovation and partnership with leading biopharma firms. The funding will support late-stage clinical development, aiming to bring new treatment options to patients with chronic immune diseases.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
